People
Solve FSHD exists to fund biotechnology and biopharmaceutical research and development efforts toward finding a treatment and cure for FSHD.
Before next-generation metabolomics becomes mainstream, the medical establishment needs to expand its mindset around cancer and translate this understanding into the clinic.
According to a BIO report, less than a third of executive team members are women. BioSpace spoke with three influential women in biopharma to get their advice on breaking the executive barrier.
Andrey Tolmachov issued a letter to the global drug discovery and scientific community, underscoring the importance of condemnation and action against Russian invasion.
Three biotech firms announced a change in leadership recently, led by Pardes Biosciences, followed by HUTCHMED and BeiGene. Read the details below.
The Phase I study could potentially result in RP-A501 becoming the first gene therapy for monogenic heart failure.
Robert Califf became the new commissioner of the U.S. Food & Drug Administration and emphasized the use of real-world evidence (RWE) in Agency decisions.
With all of this innovation coming down the pike, Gallant shared that Daiichi Sankyo is currently in growth mode, particularly when it comes to oncology.
Six months into the job, Chief Executive Officer Deepa Prasad left vTv Therapeutics. Not long ago, the former CEO dramatically slashed its workforce to ensure funding for its lead diabetes asset.
Members of the Sackler family will dedicate at least $5.5 billion plus 100% of the debtors’ assets to opioid abatement and victims.
PRESS RELEASES